Differential Expression of ID4 and Its Association with TP53 Mutation, SOX2, SOX4 and OCT-4 Expression Levels

Show simple item record

dc.contributor Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.author GALATRO, Thais Fernanda de Almeida FMUSP-HC
UNO, Miyuki FMUSP-HC
OBA-SHINJO, Sueli Mieko FMUSP-HC
ALMEIDA, Antonio Nogueira FMUSP-HC
TEIXEIRA, Manoel J. FMUSP-HC
ROSEMBERG, Sergio FMUSP-HC
MARIE, Suely Kazue N. FMUSP-HC
dc.date.issued 2013
dc.identifier.citation PLOS ONE, v.8, n.4, article ID e61605, 10p, 2013
dc.identifier.issn 1932-6203
dc.identifier.uri http://observatorio.fm.usp.br/handle/OPI/2001
dc.description.abstract Inhibitor of DNA Binding 4 (ID4) is a member of the helix-loop-helix ID family of transcription factors, mostly present in the central nervous system during embryonic development, that has been associated with TP53 mutation and activation of SOX2. Along with other transcription factors, ID4 has been implicated in the tumorigenic process of astrocytomas, contributing to cell dedifferentiation, proliferation and chemoresistance. In this study, we aimed to characterize the ID4 expression pattern in human diffusely infiltrative astrocytomas of World Health Organization (WHO) grades II to IV of malignancy (AGII-AGIV); to correlate its expression level to that of SOX2, SOX4, OCT-4 and NANOG, along with TP53 mutational status; and to correlate the results with the clinical end-point of overall survival among glioblastoma patients. Quantitative real time PCR (qRT-PCR) was performed in 130 samples of astrocytomas for relative expression, showing up-regulation of all transcription factors in tumor cases. Positive correlation was found when comparing ID4 relative expression of infiltrative astrocytomas with SOX2 (r = 0.50; p < 0.005), SOX4 (r = 0.43; p < 0.005) and OCT-4 (r = 0.39; p < 0.05). The results from TP53 coding exon analysis allowed comparisons between wild-type and mutated status only in AGII cases, demonstrating significantly higher levels of ID4, SOX2 and SOX4 in mutated cases (p < 0.05). This pattern was maintained in secondary GBM and further confirmed by immunohistochemistry, suggesting a role for ID4, SOX2 and SOX4 in early astrocytoma tumorigenesis. Combined hyperexpression of ID4, SOX4 and OCT-4 conferred a much lower (6 months) median survival than did hypoexpression (18 months). Because both ID4 alone and a complex of SOX4 and OCT-4 activate SOX2 transcription, it is possible that multiple activation of SOX2 impair the prognosis of GBM patients. These observational results of associated expression of ID4 with SOX4 and OCT-4 may be used as a predictive factor of prognosis upon further confirmation in a larger GBM series.
dc.description.sponsorship · Conselho Nacional de Pesquisa (CNPq)
· Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)
· Fundacao Faculdade de Medicina (FFM)
· Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [04/12133-6]
· Ludwig Institute for Cancer
dc.language.iso eng
dc.publisher PUBLIC LIBRARY SCIENCE
dc.relation.ispartof Plos One
dc.rights openAccess
dc.subject.other loop-helix proteins; cancer stem-cells; human astrocytomas; glioblastoma-multiforme; diffuse astrocytomas; initiating cells; mutant p53; rt-pcr; tumors; gene
dc.title Differential Expression of ID4 and Its Association with TP53 Mutation, SOX2, SOX4 and OCT-4 Expression Levels
dc.type article
dc.rights.holder Copyright PUBLIC LIBRARY SCIENCE
dc.description.group LIM/26
dc.description.group LIM/15
dc.description.group LIM/14
dc.identifier.doi 10.1371/journal.pone.0061605
dc.identifier.pmid 23613880
dc.type.category original article
dc.type.version publishedVersion
hcfmusp.author GALATRO, Thais Fernanda de Almeida:FM:
hcfmusp.author UNO, Miyuki:HC:ICESP
hcfmusp.author OBA-SHINJO, Sueli Mieko:FM:MNE
hcfmusp.author ALMEIDA, Antonio Nogueira:HC:IPQ
hcfmusp.author TEIXEIRA, Manoel J.:FM:MNE
hcfmusp.author ROSEMBERG, Sergio:FM:MPT
hcfmusp.author MARIE, Suely Kazue N.:FM:MNE
hcfmusp.origem.id 2-s2.0-84876176586
hcfmusp.origem.id WOS:000317893400078
hcfmusp.publisher.city SAN FRANCISCO
hcfmusp.publisher.country USA
hcfmusp.relation.reference · BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y
· BENEZRA R, 1990, ANN NY ACAD SCI, V599, P1, DOI 10.1111/j.1749-6632.1990.tb42359.x
· Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127
· Boiani M, 2005, NAT REV MOL CELL BIO, V6, P872, DOI 10.1038/nrm1744
· Bonavia R, 2011, CANCER RES, V71, P4055, DOI 10.1158/0008-5472.CAN-11-0153
· Chambers I, 2009, DEVELOPMENT, V136, P2311, DOI 10.1242/dev.024398
· Dell'Orso S, 2010, ONCOTARGET, V1, P48
· Fontemaggi G, 2009, NAT STRUCT MOL BIOL, V16, P1086, DOI 10.1038/nsmb.1669
· Freed-Pastor WA, 2012, GENE DEV, V26, P1268, DOI 10.1101/gad.190678.112
· Galli R, 2004, CANCER RES, V64, P7011, DOI 10.1158/0008-5472.CAN-04-1364
· Guo Y, 2011, HISTOPATHOLOGY, V59, P763, DOI 10.1111/j.1365-2559.2011.03993.x
· Holmberg J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018454
· Hur W, 2010, CARCINOGENESIS, V31, P1298, DOI 10.1093/carcin/bgq072
· Iavarone A, 2004, CANCER LETT, V204, P189, DOI 10.1016/S0304-3835(03)00455-5
· Iavarone A, 2006, TRENDS MOL MED, V12, P588, DOI 10.1016/j.molmed.2006.10.007
· Ikushima H, 2011, J BIOL CHEM, V286, P41434, DOI 10.1074/jbc.M111.300863
· Jeon HM, 2008, GENE DEV, V22, P2028, DOI 10.1101/gad.1668708
· Jeon HM, 2011, CANCER RES, V71, P3410, DOI 10.1158/0008-5472.CAN-10-3340
· Kawamura T, 2009, NATURE, V460, P1140, DOI 10.1038/nature08311
· Kuzontkoski PM, 2010, ONCOGENE, V29, P3793, DOI 10.1038/onc.2010.147
· Lin BY, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010210
· Lin TX, 2005, NAT CELL BIOL, V7, P165, DOI 10.1038/ncb1211
· Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
· Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4
· Ma YH, 2008, J NEURO-ONCOL, V86, P31, DOI 10.1007/s11060-007-9439-7
· Mallanna SK, 2012, J CELL PHYSIOL, V227, P27, DOI 10.1002/jcp.22721
· Marie SKN, 2008, INT J CANCER, V122, P807, DOI 10.1002/ijc.23189
· Martini M, 2013, CANCER-AM CANCER SOC, V119, P1004, DOI 10.1002/cncr.27821
· MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215
· Norton JD, 2000, J CELL SCI, V113, P3897
· Oba-Shinjo SM, 2005, MOL BRAIN RES, V140, P25, DOI 10.1016/j.molbrainres.2005.06.015
· Ohgaki H, 2011, BRAIN TUMOR PATHOL, V28, P177, DOI 10.1007/s10014-011-0029-1
· Ohgaki H, 2013, CLIN CANCER RES, V19, P764, DOI 10.1158/1078-0432.CCR-12-3002
· Pan X, 2009, P NATL ACAD SCI USA, V106, P3788, DOI 10.1073/pnas.0810147106
· Park Se-Jin, 2011, Lab Anim Res, V27, P333, DOI 10.5625/lar.2011.27.4.333
· Perk J, 2005, NAT REV CANCER, V5, P603, DOI 10.1038/nrc1673
· Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
· Qu QH, 2009, J CELL PHYSIOL, V221, P5, DOI 10.1002/jcp.21862
· Sampieri K, 2012, SEMIN CANCER BIOL, V22, P187, DOI 10.1016/j.semcancer.2012.03.002
· Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128
· Singh SK, 2003, CANCER RES, V63, P5821
· Uno M, 2006, INT J BIOL MARKER, V21, P50
· Uno M, 2011, CLINICS, V66, P1747, DOI 10.1590/S1807-59322011001000013
· Uno M, 2005, CANCER LETT, V224, P321, DOI 10.1016/j.canlet.2004.10.022
· Valente V, 2009, BMC MOL BIOL, V10, DOI 10.1186/1471-2199-10-17
· Vandeputte DAA, 2002, GLIA, V38, P329, DOI 10.1002/glia.10076
· Wu QO, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-16
· Yuan XP, 2004, ONCOGENE, V23, P9392, DOI 10.1038/sj.onc.1208311
· Yun K, 2004, DEVELOPMENT, V131, P5441, DOI 10.1242/dev.01430
· Zeng WF, 2010, J CANCER, V1, P1
dc.description.index MEDLINE
hcfmusp.citation.scopus 11
hcfmusp.citation.wos 12


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace



Browse

My Account

Statistics